GH001
Phase 2Small molecule
GH001 is one of 43 small molecule programs targeting Bipolar II Disorder. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
50 competitors in Postpartum Depression
#DrugCompanyPhaseTrials
1Zulresso
BiogenApproved
Estrace
Novo NordiskApproved
Zoloft
VViatris Specialty LLC
Approved
Ketalar
AAultman Health Foundation
Approved
Prometrium
FerringApproved
Ultram
WWim Janssens
Approved
Naropin
FFresenius Kabi Oncology Ltd.
Approved
Dilaudid
RRhodes Pharmaceuticals, L.P.
Approved
Sufenta
LLeaf Vertical Inc.
Approved
Abilify
OtsukaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GH001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- GGH Research Ireland Limited